SK Capital Partners agreed to buy a majority stake in Swixx Biopharma SA in a deal that values the Swiss drug distribution company at more than €1.5 billion ($1.8 billion).
As part of the transaction, HBM Healthcare Investments AG, Swixx founders and other shareholders including Merieux Equity Partners will sell a majority of their holding to SK Capital, according to a statement on Monday, which confirmed an earlier Bloomberg News report.
The transaction is likely to be completed in the first half of 2026, after which HBM expects to receive a cash inflow exceeding the investment’s reported book ...
